Leukemia Clinical Trials in Birmingham

10 recruitingBirmingham, United Kingdom

Showing 110 of 10 trials

Recruiting
Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled112 locationsNCT06846671
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

Chronic Lymphocytic Leukemia (CLL)
AstraZeneca350 enrolled29 locationsNCT05557695
Recruiting
Phase 2

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 3

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 3

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Phase 3

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Leukemia, Acute Lymphoblastic
Mats Heyman6,430 enrolled130 locationsNCT04307576
Recruiting
Phase 3

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Phase 3

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Acute Myeloid Leukemia, Adult
Stichting Hemato-Oncologie voor Volwassenen Nederland415 enrolled67 locationsNCT06652438
Recruiting
Phase 1Phase 2

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Sumitomo Pharma America, Inc.362 enrolled92 locationsNCT04988555